May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 27, 2025

Gene Therapy Trial Halted After Fatal Turn

A gene therapy trial for Danon disease is on FDA hold after a patient death tied to a new immune-suppressing agent

Reuters

May 27, 2025

Mucous Membrane Pemphigoid Linked to Higher Skin Cancer Risk

Investigators found that patients with mucous membrane pemphigoid, especially those with severe disease, face increased risks of squamous and basal cell carcinomas.

Conexiant

May 23, 2025

Early-Phase Trial Shows Activity and Safety of Zongertinib in Previously Treated HER2-Mutant NSCLC

Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated...

The ASCO Post

May 23, 2025

Fellows of the AACR Academy Class of 2025

Listed here is the newly elected 2025 class of Fellows of the American Academy for Cancer Research (AACR) Academy, which was recognized at the AACR Annual Meeting, April 25–30, 2025, in Chicago. 

The ASCO Post

May 23, 2025

Early-Stage Nonrectal Mismatch Repair–Deficient Tumors Respond to Neoadjuvant PD-1 Blockade, Facilitating Nonoperative Management

Mismatch repair–deficient (dMMR) tumors beyond those in the rectum may respond to PD-1 blockade in the neoadjuvant setting, offering the option of organ preservation in early-stage cancer regardless o...

The ASCO Post

May 22, 2025

At-Home HPV Test Matches Clinic Accuracy

Researchers found that an at-home self-collection device for HPV testing demonstrated high accuracy and safety, matching clinician-collected results for cervical cancer screening.

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 22, 2025

Extensive-Stage SCLC: Lurbinectedin and Atezolizumab

Results from the global phase III IMforte trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some p...

The ASCO Post